Matt has been a healthcare-focused venture capital investor since 1980. He began his venture capital career with Citicorp Venture Capital, where he was VP and a member of the investment executive committee. Matt later joined Robertson, Stephens & Co. and was partner and Chairman of the Venture Capital Group. In 1991 he formed Mackowski & Shepler, an investment partnership focused on developing life science and medical technology companies and the predecessor to THP. Matt has represented THP on the boards of Althea Technologies (acquired by Ajinomoto), AltheaDx, Ambion (acquired by Applied Biosystems), Asuragen (acquired by Bio-Techne), Aurora Discovery (acquired by NEXUS Biosystems), Emerging Therapy Solutions, Interface Associates (acquired by NDC), Kinetikos Medical (acquired by Integra), Magstim, MedPricer (acquired by Premier), and TrakCel (NASDAQ:TKNO). Matt received a BA from Duke University and an MBA from The Wharton School.
J. Matthew Mackowski
Chairman, Managing Director